PCSA
Processa Pharmaceuticals, Inc. NASDAQ$2.68
Mkt Cap $6.1M
52w Low $1.76
5.1% of range
52w High $19.62
50d MA $2.69
200d MA $4.77
P/E (TTM)
-0.2x
EV/EBITDA
0.1x
P/B
0.6x
Debt/Equity
0.0x
ROE
-243.2%
P/FCF
-0.3x
RSI (14)
—
ATR (14)
—
Beta
0.89
50d MA
$2.69
200d MA
$4.77
Avg Volume
56.1K
About
Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase 2B clinical trials for the treatment of ulcerative and non-ulcerative necrobiosis lipoidica, a chronic disfiguring condition. The com…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | 1M% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 19, 2026 | AMC | -1.50 | -18.50 | -1133.3% | 2.33 | -1.7% | -0.4% | +0.9% | +0.0% | -1.3% | -3.9% | +16.3% | — |
| Nov 6, 2025 | AMC | -2.00 | -1.75 | +12.5% | 7.90 | -5.1% | -3.2% | +9.2% | +0.0% | +3.2% | -7.6% | -10.1% | — |
| Aug 7, 2025 | AMC | -0.23 | -0.25 | -8.7% | 5.78 | -0.5% | +0.3% | -3.5% | -4.5% | -1.4% | -4.7% | -21.1% | — |
| May 8, 2025 | AMC | -0.77 | -0.30 | +61.0% | 6.85 | -1.9% | -12.7% | -12.8% | -16.4% | -14.6% | -9.8% | +18.5% | — |
| Mar 20, 2025 | AMC | -0.92 | -0.74 | +19.6% | 10.63 | +1.7% | +1.1% | +3.1% | -5.9% | -7.9% | -8.3% | -48.3% | — |
| Oct 30, 2024 | AMC | -1.00 | -1.03 | -3.0% | 33.25 | +0.0% | -12.8% | -13.5% | -16.5% | -17.3% | -15.8% | -12.8% | — |
| Aug 13, 2024 | AMC | -0.98 | -1.01 | -3.1% | 34.00 | +0.7% | -0.7% | -3.7% | +6.6% | +11.8% | +11.0% | -1.5% | — |
| May 10, 2024 | AMC | -1.18 | -1.11 | +5.9% | 52.25 | +4.8% | +6.2% | +4.3% | -3.3% | -4.3% | -6.2% | -24.4% | — |
| Mar 29, 2024 | AMC | -1.60 | -0.24 | +85.0% | — | — | — | — | — | — | — | — | — |
| Nov 13, 2023 | AMC | -0.10 | -1.60 | -1500.0% | 189.00 | +4.5% | +8.7% | +4.2% | +10.1% | +13.8% | +12.4% | +60.1% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sep 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.72 | $4.72 | +0.0% | -0.4% | -0.6% | -10.2% | -8.9% | -3.4% |
| Jun 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.91 | $5.03 | +2.4% | +4.5% | +1.8% | -4.1% | -0.8% | -1.2% |
| Dec 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $25.25 | $25.25 | +0.0% | +1.0% | +2.0% | +23.8% | +31.7% | +24.8% |
| Aug 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $38.00 | $36.75 | -3.3% | -0.7% | +0.7% | -2.6% | -4.6% | -4.6% |
| Aug 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $36.25 | $35.25 | -2.8% | +4.8% | +4.1% | +5.5% | +2.1% | +0.0% |
| Aug 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $52.50 | $53.00 | +1.0% | -0.5% | -8.6% | -15.2% | -11.4% | -14.8% |
| Jun 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $45.00 | $44.25 | -1.7% | -11.1% | -8.3% | -2.8% | +2.8% | +1.7% |
| May 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $52.25 | $54.75 | +4.8% | +6.2% | +4.3% | -3.3% | -4.3% | -6.2% |
| Mar 6 | Benchmark | Maintains | Speculative Buy → Speculative Buy | — | $57.00 | $61.25 | +7.5% | +1.8% | +1.3% | -0.4% | +0.0% | -0.4% |
| Nov 17 | Maxim Group | Downgrade | Buy → Hold | — | $208.00 | $217.50 | +4.6% | +3.4% | +2.2% | -4.3% | +4.6% | +13.0% |
Recent Filings
8-K · 5.03
! Medium
Unknown — 8-K 5.03: Amendment to Articles / Bylaws
Two healthcare/biotech companies added a blockchain and health informatics expert to leadership, signaling strategic focus on data integrity and emerging tech applications—potentially improving clinical trial credibility and operational efficiency.
Mar 20
8-K · 1.02
!! High
Processa Pharmaceuticals, Inc. Common -- 8-K 1.02: Material Agreement Terminated
Processa Pharmaceuticals' licensing agreement with Intact Therapeutics for PCS12852 expired without a definitive deal, eliminating a planned collaboration and potentially affecting the drug's development timeline and partnership prospects.
Feb 19
Data updated apr 26, 2026 6:59pm
· Source: massive.com